A NLC system was developed for the oral co-delivery of raloxifene, a synthetic selective estrogen receptor modulator, and naringin, a flavonoid phytochemical with known anticancer activity, targeting estrogen receptor–positive breast cancer [235]. This evidence concerns the gene ESR1 and breast carcinoma.